Botanix soars after pot-up-nose study success


‘Botanix Pharmaceuticals (ASX:BOT) shares have soared after a small clinical trial backed the feasibility of putting synthetic cannabis up the nose of surgical patients to prevent infections.

While cannabis is of course mostly known for its psychoactive properties, a number of companies trying to unlock its therapeutic benefit and Botanix’s research has shown that cannabidiol (CBD) is a potent antimicrobial.’

Click through to read the full article on Stockhead.